100 related articles for article (PubMed ID: 29901072)
1. Anticancer and radiosensitizing effects of the cyclin-dependent kinase inhibitors, AT7519 and SNS‑032, on cervical cancer.
Kang MA; Kim W; Jo HR; Shin YJ; Kim MH; Jeong JH
Int J Oncol; 2018 Aug; 53(2):703-712. PubMed ID: 29901072
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of cyclin-dependent kinases by AT7519 is effective to overcome chemoresistance in colon and cervical cancer.
Xi C; Wang L; Yu J; Ye H; Cao L; Gong Z
Biochem Biophys Res Commun; 2019 Jun; 513(3):589-593. PubMed ID: 30979499
[TBL] [Abstract][Full Text] [Related]
3. Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines.
Squires MS; Feltell RE; Wallis NG; Lewis EJ; Smith DM; Cross DM; Lyons JF; Thompson NT
Mol Cancer Ther; 2009 Feb; 8(2):324-32. PubMed ID: 19174555
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of cyclin-dependent kinases by AT7519 enhances nasopharyngeal carcinoma cell response to chemotherapy.
Wei X; Nian J; Zheng J; He Y; Zeng M
Cancer Chemother Pharmacol; 2020 May; 85(5):949-957. PubMed ID: 32279103
[TBL] [Abstract][Full Text] [Related]
5. Synergistic antitumor effects of CDK inhibitor SNS‑032 and an oncolytic adenovirus co‑expressing TRAIL and Smac in pancreatic cancer.
Ge Y; Lei W; Ma Y; Wang Y; Wei B; Chen X; Ru G; He X; Mou X; Wang S
Mol Med Rep; 2017 Jun; 15(6):3521-3528. PubMed ID: 28440486
[TBL] [Abstract][Full Text] [Related]
6. AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition.
Santo L; Vallet S; Hideshima T; Cirstea D; Ikeda H; Pozzi S; Patel K; Okawa Y; Gorgun G; Perrone G; Calabrese E; Yule M; Squires M; Ladetto M; Boccadoro M; Richardson PG; Munshi NC; Anderson KC; Raje N
Oncogene; 2010 Apr; 29(16):2325-36. PubMed ID: 20101221
[TBL] [Abstract][Full Text] [Related]
7. The cyclin-dependent kinase inhibitor AT7519 augments cisplatin's efficacy in ovarian cancer via multiple oncogenic signaling pathways.
Wang L; Chen Y; Li H; Xu Q; Liu R
Fundam Clin Pharmacol; 2022 Feb; 36(1):81-88. PubMed ID: 34212421
[TBL] [Abstract][Full Text] [Related]
8. Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells.
Raju U; Nakata E; Mason KA; Ang KK; Milas L
Cancer Res; 2003 Jun; 63(12):3263-7. PubMed ID: 12810657
[TBL] [Abstract][Full Text] [Related]
9. AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples.
Squires MS; Cooke L; Lock V; Qi W; Lewis EJ; Thompson NT; Lyons JF; Mahadevan D
Mol Cancer Ther; 2010 Apr; 9(4):920-8. PubMed ID: 20354122
[TBL] [Abstract][Full Text] [Related]
10. AT7519 against lung cancer via the IL6/STAT3 signaling pathway.
Zhou F; Zhu F; Zhu T; Zhao Z; Li L; Lin S; Zhao H; Yang L; Zhao C; Wang L; Li J; Huang X
Biochem Biophys Res Commun; 2022 Jun; 609():31-38. PubMed ID: 35413537
[TBL] [Abstract][Full Text] [Related]
11. Transient treatment with CDK inhibitors eliminates proliferative potential even when their abilities to evoke apoptosis and DNA damage are blocked.
Scrace SF; Kierstan P; Borgognoni J; Wang LZ; Denny S; Wayne J; Bentley C; Cansfield AD; Jackson PS; Lockie AM; Curtin NJ; Newell DR; Williamson DS; Moore JD
Cell Cycle; 2008 Dec; 7(24):3898-907. PubMed ID: 19066469
[TBL] [Abstract][Full Text] [Related]
12. Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
Shirsath N; Rathos M; Chaudhari U; Sivaramakrishnan H; Joshi K
Lung Cancer; 2013 Nov; 82(2):214-21. PubMed ID: 24051085
[TBL] [Abstract][Full Text] [Related]
13. Identification of potent pyrazolo[4,3-h]quinazoline-3-carboxamides as multi-cyclin-dependent kinase inhibitors.
Traquandi G; Ciomei M; Ballinari D; Casale E; Colombo N; Croci V; Fiorentini F; Isacchi A; Longo A; Mercurio C; Panzeri A; Pastori W; Pevarello P; Volpi D; Roussel P; Vulpetti A; Brasca MG
J Med Chem; 2010 Mar; 53(5):2171-87. PubMed ID: 20141146
[TBL] [Abstract][Full Text] [Related]
14. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
Roskoski R
Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
[TBL] [Abstract][Full Text] [Related]
15. Improvement of esophageal adenocarcinoma cell and xenograft responses to radiation by targeting cyclin-dependent kinases.
Raju U; Ariga H; Koto M; Lu X; Pickett J; Valdecanas D; Mason KA; Milas L
Radiother Oncol; 2006 Aug; 80(2):185-91. PubMed ID: 16905211
[TBL] [Abstract][Full Text] [Related]
16. Radiosensitizing Effect of Novel Phenylpyrimidine Derivatives on Human Lung Cancer Cells via Cell Cycle Perturbation.
Jung SY; Nam KY; Park JI; Song KH; Ahn J; Park JK; Um HD; Hwang SG; Choi SU; Song JY
J Pharmacol Exp Ther; 2019 Sep; 370(3):514-527. PubMed ID: 31253693
[TBL] [Abstract][Full Text] [Related]
17. A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177.
Chen EX; Hotte S; Hirte H; Siu LL; Lyons J; Squires M; Lovell S; Turner S; McIntosh L; Seymour L
Br J Cancer; 2014 Dec; 111(12):2262-7. PubMed ID: 25393368
[TBL] [Abstract][Full Text] [Related]
18. Rhabdoid tumor growth is inhibited by flavopiridol.
Smith ME; Cimica V; Chinni S; Challagulla K; Mani S; Kalpana GV
Clin Cancer Res; 2008 Jan; 14(2):523-32. PubMed ID: 18223228
[TBL] [Abstract][Full Text] [Related]
19. Human Papillomavirus E6/E7-Specific siRNA Potentiates the Effect of Radiotherapy for Cervical Cancer in Vitro and in Vivo.
Jung HS; Rajasekaran N; Song SY; Kim YD; Hong S; Choi HJ; Kim YS; Choi JS; Choi YL; Shin YK
Int J Mol Sci; 2015 May; 16(6):12243-60. PubMed ID: 26035754
[TBL] [Abstract][Full Text] [Related]
20. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis.
Patel V; Senderowicz AM; Pinto D; Igishi T; Raffeld M; Quintanilla-Martinez L; Ensley JF; Sausville EA; Gutkind JS
J Clin Invest; 1998 Nov; 102(9):1674-81. PubMed ID: 9802881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]